Three peptides: GHK-Cu, BPC-157 and TB-500. Each has its own published literature; the combination has none.

Has GLOW-70 been studied?

No published study investigates this three-component combination. Everything known about the contents comes from work on the individual peptides, tested separately.

Why does the number of components matter?

Because attribution gets harder faster than the ingredient list grows. Three components mean three candidate explanations plus their pairwise and three-way interactions for any observation made with the vial.

Which component has the strongest evidence?

GHK-Cu, whose published work spans wound models, gene expression and cosmetic dermatology. That does not transfer to the blend — it is evidence about one of three things in the vial.

Is GLOW-70 approved as a medicine?

No, in any jurisdiction, and neither is any of its components. It is supplied here as a laboratory reagent for in-vitro research only.

Research guides

GLOW-70 blend (GHK-Cu, BPC-157, TB-500)

Three peptides in one vial and no published study of the three together. What each component's literature covers, and why three components is harder than two.

Available in the catalogue

Supplied as research material. Sizes and pricing are on the product page. Availability is not a statement about what a compound does.

GLOW-70
Cosmetic & Dermal

GLOW-70 is a three-component blend, and each component added multiplies the distance between what has been studied and what is in the vial.

What is in the vial

GHK-Cu, a copper-binding tripeptide with a substantial dermatological and cell-culture literature; BPC-157, a gastric-juice-derived pentadecapeptide; and TB-500, a fragment associated with thymosin β4. All three have their own articles.

Why three is harder than two

With two components, an unattributable observation has two candidate explanations plus their interaction. With three, it has three candidates, three pairwise interactions and one three-way interaction. Nothing about the biology gets harder; the inference does, and it gets harder faster than the ingredient list grows.

That is the practical argument against a multi-component vial as a research tool, and it holds regardless of how well supported each component is on its own.

What the components have in common

GHK-Cu is the best-evidenced of the three, with published work spanning wound models, gene expression and cosmetic dermatology. BPC-157 and TB-500 both carry structural caveats — a literature concentrated in one research group, and a fragment that is not the molecule most of the parent literature studied. A blend does not average those out.

What studies reported

Each entry states what a study examined and the model it used. Nothing below describes an outcome for a person.

Everything below is drawn from published research, and each entry names the model the study used. Approval status varies by compound and by country, and nothing described here is supplied as a medicine or for use in a person.

Adverse and null findings reported

No dedicated safety study has been published for this compound. That is not a finding that none exists — it means the question has not been asked in print, and the gaps below say so.

What the research does not establish

An absence cannot be cited, so these are stated plainly. They are the part of the picture that silence would otherwise hide.

No published study investigates this combination. Everything known about the contents of this vial comes from work on the individual components, tested separately.
With three active components, an observation made with this vial has three candidate explanations plus their interactions, and nothing published allows them to be separated.
No published work establishes a basis for the proportions in which the three are combined.
The individual caveats carry over: BPC-157's in-vivo literature comes largely from one research group, and the fragment sold as TB-500 is not the thymosin β4 molecule most of that literature studied.
GHK-Cu carries copper, and none of the published work on the blend — because there is none — addresses what combining a copper-carrying peptide with two others in a fixed ratio means.
No safety study of this combination has been published.

Common questions

What is in GLOW-70?: Three peptides: GHK-Cu, BPC-157 and TB-500. Each has its own published literature; the combination has none.
Has GLOW-70 been studied?: No published study investigates this three-component combination. Everything known about the contents comes from work on the individual peptides, tested separately.
Why does the number of components matter?: Because attribution gets harder faster than the ingredient list grows. Three components mean three candidate explanations plus their pairwise and three-way interactions for any observation made with the vial.
Which component has the strongest evidence?: GHK-Cu, whose published work spans wound models, gene expression and cosmetic dermatology. That does not transfer to the blend — it is evidence about one of three things in the vial.
Is GLOW-70 approved as a medicine?: No, in any jurisdiction, and neither is any of its components. It is supplied here as a laboratory reagent for in-vitro research only.

Compounds covered

The reference page for each compound this article discusses.

GLOW-70

GHK-Cu copper peptide: what the research says
The copper tripeptide GHK-Cu has the strongest published evidence of any repair peptide here, spanning wound models, gene expression and cosmetic dermatology.
BPC-157 and TB-500 blend: what the research says
Two repair peptides in one vial and no published study of the pair. What each component's literature covers, and why a blend is weaker evidence than its parts.
KLOW-80 blend (GHK-Cu, BPC-157, TB-500, KPV)
Four peptides in one vial, and the attribution problem at its most acute: nothing observed with the mixture can be traced to any single component.

About this article

Everything reported here comes from published research, and each finding names the model the study used — cell culture, rat, or human. Findings in one model do not transfer to another, most of the work described is preclinical, and none of it is a claim that a compound is safe or effective for any purpose. Nothing on this page describes doses, routes of administration, or use in a person.

Approval status varies by compound and by country. A few of the substances described are the active ingredient of medicines authorised in the EU; most have no marketing authorisation anywhere and have never been assessed by a regulator. Neither is supplied as a medicine here. All material supplied by ASSAY is sold for in-vitro laboratory research only, and is not a drug, food, cosmetic or medical device, and not for human or veterinary use.

All guides